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the prevalence of diabetic metabolic derangement (DMetD) has increased dramatically over the last 
decades. Although there is increasing evidence that DMetD is associated with cardiac dysfunction, the 
early DMetD-induced myocardial alterations remain incompletely understood. Here, we studied early 
DMetD-related cardiac changes in a clinically relevant large animal model. DMetD was established 
in adult male Göttingen miniswine by streptozotocin injections and a high-fat, high-sugar diet, 
while control animals remained on normal pig chow. five months later left ventricular (LV) function 
was assessed by echocardiography and hemodynamic measurements, followed by comprehensive 
biochemical, molecular and histological analyses. Robust DMetD developed, evidenced by 
hyperglycemia, hypercholesterolemia and hypertriglyceridemia. DMetD resulted in altered LV nitroso-
redox balance, increased superoxide production—principally due to endothelial nitric oxide synthase 
(enoS) uncoupling—reduced nitric oxide (no) production, alterations in myocardial gene-expression—
particularly genes related to glucose and fatty acid metabolism—and mitochondrial dysfunction. 
these abnormalities were accompanied by increased passive force of isolated cardiomyocytes, 
and impaired LV diastolic function, evidenced by reduced LV peak untwist velocity and increased 
e/e′. However, LV weight, volume, collagen content, and cardiomyocyte cross-sectional area were 
unchanged at this stage of DMetD. in conclusion, DMetD, in a clinically relevant large-animal model 
results in myocardial oxidative stress, enoS uncoupling and reduced no production, together with an 
altered metabolic gene expression profile and mitochondrial dysfunction. These molecular alterations 
are associated with stiffening of the cardiomyocytes and early diastolic dysfunction before any 
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structural cardiac remodeling occurs. therapies should be directed to ameliorate these early DMetD-
induced myocardial changes to prevent the development of overt cardiac failure.
According to a recent report by World Health Organization, age-standardized global prevalence of diabetes 
has nearly doubled since 1980, rising from 4.7% to 8.5% in the adult population.1 An estimated 422 million 
adults suffered from diabetes mellitus in 2014, compared to 108 million in 1980, which is the result of concomi-
tantly increased prevalence of obesity and overweight  globally1. As diabetes is associated with increased risk 
of cardiovascular diseases in particular, a deeper understanding of its cardiac pathophysiology is essential for 
the development of novel targeted treatments. Previous pre-clinical studies have addressed the consequences 
of diabetes in myocardial tissue, showing that the pathophysiology of diabetes-induced cardiac damage is a 
complex and multifactorial process, in which oxidative stress has been postulated as a key  player2–6. Indeed, 
increased reactive oxygen species production and reduced antioxidant defenses have been associated with dia-
betic  cardiomyopathy2–5. However, the majority of these studies have been performed in  rodents2–4 and it remains 
uncertain whether these findings can be translated to a larger, human-like heart.
Consequently, in the present study we employed a translationally relevant large animal model with Diabetic 
Metabolic Derangement (DMetD), having similar anatomic, physiologic and metabolic characteristics of the 
cardiovascular system with the human situation. We characterized, in adult swine, the early DMetD-induced 
left ventricular (LV) changes at the mRNA, protein, cellular, tissue and organ function levels. For this purpose, 
DMetD was produced in adult male Göttingen miniswine by streptozotocin injections, to result in partial destruc-
tion of the pancreatic β-cells leading to impaired insulin production, combined with a high-fat, high sucrose and 
high fructose diet. LV function was assessed at baseline and 5 months after induction of DMetD, and myocardial 
tissue was comprehensively analyzed for oxidative stress and nitric oxide (NO) production, mitochondrial func-
tion, cardiomyocyte function, collagen content, and global LV remodeling and function, as well as for genome-
wide gene expression profile. Our study shows that DMetD results in myocardial oxidative stress, endothelial 
nitric oxide synthase (eNOS) uncoupling and reduced NO production together with mitochondrial dysfunction 
and alterations in metabolic gene expression profile. These abnormalities are associated with impaired LV relaxa-
tion, at a time when cardiac structural remodeling at either the global LV or myocardial tissue level is still absent.
Methods
Animals and DMetD induction. Studies were performed in accordance with the NIH Guide for the Care 
and Use of Laboratory Animals (8th edition, National Research Council. Washington, DC: The National Acad-
emies Press, 2011) and were approved by the Animal Care Committee at Erasmus University Medical Center, 
Rotterdam, The Netherlands. A total of 17 adult male Göttingen minipigs were enrolled in the study and fol-
lowed for 5 months. Diabetes was induced in 9 swine with intravenous injections of streptozotocin (25 mg/kg/
day), over three  days7. One week later, a high fat and high sugar diet (25% saturated fats, 1% cholesterol, 10% 
sucrose and 15% fructose) was gradually introduced to the diabetic swine (DMetD group, N = 9), whereas the 
healthy control swine (Control, N = 8) continued on normal pig chow. Swine were group-housed with a separate 
individual access to food for 1 h/meal, twice daily, and ad libitum access to water. Fasting mixed central venous 
blood samples were obtained at baseline and sacrifice (5-month time point), and analyzed for glucose, triglyc-
eride and cholesterol.
fitness test. To objectively measure physical fitness, animals were subjected to an incremental endurance 
treadmill test until exhaustion. The test started at a pace of 1.5 km/h and speed was increased by 0.5 km/h every 
five minutes and running time was recorded as an indicator of maximal aerobic endurance capacity.
echocardiography. Echocardiography was performed at baseline, and after 5  months. Animals were 
sedated with an intramuscular injection of Zoletil (tiletamine/zolazepam; 5 mg/kg) and xylazine (2.25 mg/kg). 
Two-dimensional echocardiographic images (iE33, Philips, Best, the Netherlands) were acquired in harmonic 
mode from a right lateral decubitus position using a broadband (1–5 MHz) X5-1 transducer. All acquisitions 
and measurements were performed according to the current  guidelines8. We performed pulsed-wave Doppler 
examination from the (apical) 4-chamber view, to obtain peak mitral inflow velocities at early (E) and late (A) 
diastole and E deceleration time. Tissue Doppler imaging was performed to measure myocardial tissue velocity 
at the septal and lateral mitral annulus at early diastole (e′). E/A ratio and the E/e′ ratio were calculated. Left 
atrial volume was measured using the modified biplane area-length method. Left atrial volume index was calcu-
lated by dividing left atrial volume by body weight.
Hemodynamic assessments and cardiac tissue sampling and analyses. At 5 months follow up, 
hemodynamic measurements were perfomed under anesthesia and animals were terminated. Sedation was 
induced with Zoletil (tiletamine/zolazepam; 5 mg/kg), xylazine (2.25 mg/kg) and atropine (2 ml i.m.), and ani-
mals were anesthetized with an intravenous continuous infusion of pentobarbital (20 mg/kg), intubated and 
artificially ventilated. Arterial and venous access was obtained by placing 9F sheaths in the left carotid artery and 
the jugular vein for the measurement of mean aortic pressure, LV pressure (using a Millar catheter), as well as 
pulmonary artery and pulmonary capillary wedge pressure, cardiac output (by thermodilution) and for blood 
sampling. After placing a pressure-volume catheter in the LV (PV loop catheter, CD Leycom, The Netherlands), 
the pressure–volume loops were recorded and end-diastolic pressure–volume relationships were constructed, 
during baseline hemodynamic conditions, preload reduction (by complete obstruction of the inferior vena cava 
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by a Fogarty balloon, 8/10F, Edwards Life sciences, Amsterdam, The Netherlands) and preload increase (by 
saline infusion, 20 ml/kg i.v. within 7 min). Thereafter, a sternotomy was performed, hearts were arrested, and 
quickly excised, washed in cold saline solution and then rapidly cut and frozen in liquid nitrogen and prepared 
and stored for later analyses.
Myocardial reactive oxygen species (RoS) and nitric oxide (no) production measure-
ments. Cardiac oxidative stress was evaluated by lucigenin-enhanced chemiluminescence (Sigma Aldrich; 
5 μmol/l) as previously  described7. To this end, both basal and NADPH-stimulated (300 μM NADPH) superox-
ide generation were measured in homogenized, frozen sub-endocardial tissue samples of the anterior LV wall. 
NOS-dependent superoxide production was determined by incubating the samples for 20 min with the NOS 
inhibitor L-NAME (Sigma Aldrich; 1 mmol/l), while the contribution of NADPH oxidase to superoxide pro-
duction was assessed using the NADPH oxidase inhibitor VAS2870, (10 μM). The temperature was controlled 
(37 °C) during the entire experiment and the measured light emission was expressed as relative light units (RLU) 
per mg protein per second. All samples were measured in duplicate and data averaged for each animal.
Aditionally, myocardial NO production was evaluated in the same area, by measuring the production of NO 
metabolites  NO2- and  NO3- using the Griess reaction colorimetric assay kit (Cayman Chemical).
endothelial nitric oxide synthase expression and phosphorylation. Protein expression of endothe-
lial nitric oxide synthase (eNOS) and the phosphorylated eNOS were determined in homogenized, snap frozen 
LV sub-endocardial tissue samples. Furthermore, low temperature SDS-PAGE was performed for the detection 
of eNOS monomer and dimer fraction, as previously  described9. SDS-PAGE for phosphorylated eNOS, total 
eNOS protein content and housekeeping protein glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was 
performed at room temperature. Subsequently, proteins were transferred onto nitrocellulose membranes and the 
blots were probed with primary anti-phospho eNOS (1:1,000, Cell Signaling), anti-eNOS (1:500, Transduction 
Laboratory) and anti-GAPDH (1:10,000, Imgenex). All blots were analysed using the Odyssey system (LI-COR).
AMpK western blot analyses. Frozen LV samples were weighed and homogenized in 6 vol ice cold 
62.5 mM Tris–HCl buffer (pH 6.8, with 1 μg/ml Leupeptin, 1 μg/ml Pepstatin, and 1 mM phenylmethanesulfo-
nyl fluoride, Sigma-Aldrich, St. Louis, Missouri, USA) with Qiagen TissueLyser (85220, Hilden, Germany). The 
homogenates were centrifuged and the samples were then denatured in Laemmli solution at + 70 °C for 7 mins10. 
Protein concentration of samples was determined using BCA protein assay kit (Thermo Scientific, Waltham, 
Massachusetts, USA). The samples (10 μg of protein for antibodies AMPK and pAMPK) were run with SDS-
PAGE gels. After separation, the proteins were transferred onto a Whatman Protran Nitrocellulose membrane 
(PerkinElmer, Boston, Massachusetts, USA). The immunoblot membranes were blocked with 5% bovine serum 
albumin (BSA, Sigma-Aldrich) in Tris buffered saline (TBS, Sigma-Aldrich and thereafter, the membranes where 
incubated overnight at + 4 °C with primary antibodies for AMPK and pAMPK, washed and then incubated for 
30 min with horseradish peroxidase conjugated secondary anti-rabbit antibody (1:10,000, Abcam, ab6721). The 
band densities were analysed with Gel Doc XR System (BioRad). In order to avoid variation between membranes 
a control sample was loaded onto each gel and the band intensities were normalized against the control sample.
enzyme assays. The samples were weighed and homogenized with 10 volumes of ice-cold homogenization 
solution (50 mM imidazole, 1 mM EDTA, pH 8.0) for HOAD (EC 1.1.1.35) or with 19 volumes homogenization 
buffer (50 mM Hepes, 1 mM, EDTA, 0.1% Triton X-100, pH 7.4) for CS (EC 2.3.3.1) and Lactate Dehydrogenase 
(LDH) (EC 1.1.1.27) with Qiagen TissueLyser. The HOAD samples were diluted 1:1 with homogenization solu-
tion, the LDH samples were diluted 1:1 with 50 mM Tris buffer, pH 7.4 and the CS samples were diluted 1:8 with 
50 mM Tris buffer, pH 8.0. The protein concentrations of samples were determined with a BCA protein assay kit 
following the manufacturer´s protocol. The enzyme activity analyses were performed according to Dalziel et al.11 
for CS and LDH and according to Lowry et al.12 for HOAD at 37 °C. The activities were read with PerkinElmer 
Enspire 2,300 Multilaber reader (Turku, Finland), and the enzyme activities were calculated per mg protein with 
the background activity subtracted.
Histology and immunohistochemistry. After the heart was excised, LV myocardial tissue samples were 
fixated in 4% buffered formaldehyde, and embedded in paraffin. Thereafter, 4.5 μm thick slides were cut from 
the LV anterior wall, deparaffinized and stained for various histological analyses. For each analysis, 6–10 fields 
at × 20 magnification, were examined in the sub-endocardium of each slide. Collagen deposition was quanti-
fied using Picrosirius Red staining as follows: using a linear polarization filter, the area occupied by the collagen 
type I and type III fibers, was measured and expressed as percentage of the myocardial area. Myocyte size was 
quantified with a Gomori silver stain: cross-sectional areas of 300–350 round cells with clearly visible nuclei 
were measured in each slide. All measurements were performed using the Clemex Vision Image analysis system 
(Clemex Technologies, Quebec, Canada).
Passive cardiomyocyte stiffness and titin isoform composition. Passive stiffness of single cardio-
myocytes was measured using membrane-permeabilized cardiomyocytes. In brief, single cardiomyocytes were 
isolated in cold relaxing solution containing (in mM) free  Mg2+ 1, KCl 100, EGTA 2, Mg-ATP 4, imidazole 10 
(pH 7.0, adjusted with KOH) and incubated for 5 min in relaxing solution containing Triton X-100 (0.5%) to 
remove all membranes as described  previously13. Passive stiffness of the cardiomyocytes, was assesed by Fpas 
measurements, performed in relaxing solution at 15 °C and at sarcomere lengths ranging from 1.8 to 2.2 μm. 
4
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:13173  | https://doi.org/10.1038/s41598-020-68637-4
www.nature.com/scientificreports/
Cardiomyocyte diameters were measured microscopically, in two perpendicular directions, and cross-sectional 
area was calculated assuming an elliptical shape. Passive force data were normalized to cross-sectional area of 
cardiomyocytes. Titin isoforms were separated on 1% agarose gel and stained with SYPRO Ruby protein stain 
as described  previously14,15.
electron microscopy analysis of mitochondria. LV samples of 6 Control and 5 DMetD animals were 
prepared for electron microscopy as previously  described16. In short, samples were fixed in 1.5% osmium tetrox-
ide (10  min), dehydrated with acetone, and embedded in Epon812. Ultrathin sections were cut and placed 
on 300-mesh Formavar-coated nickel grids, and stained with uranyl acetate and lead citrate. Images from the 
intramyofibrillar region (longitudinal to the fiber orientation only) were taken at magnifications ranging from 
4,500 × to 30,000 × with an electron microscope (Jeol-1200EX, Jeol Peabody, MA, USA). Glycogen content and 
the number of vacuoles were determined by scoring images on a scale for 1 (low) to 5 (extremely high) in a 
blinded fashion. Mitochondrial volume density was determined by overlaying a dense grid over images taken at 
22,500 × and counting all mitochondria overlaying grid corners, as a percentage of all grid corners. Mitochon-
drial connectivity was assessed by visually inspecting whether mitochondria were touching other mitochondria, 
and expressed as a percentage of all mitochondria on the image. On average, 8 ± 1 images were analyzed per 
animal.
Mitochondrial respiration. Mitochondrial respiration was measured in fresh biopsies from the LV sub-
endocardium as described  before16. Thin strips were permeabilised with saponin (50 µg/ml) for 30 min at 4 °C in 
a solution consisting of 7.2 mM EGTA, 2.8 mMCaEGTA, 6.6 mM  MgCl2, 10 mM taurine, 5.8 mM ATP, 15 mM 
phosphocreatine, 20 mM imidazole, 50 mM MES and 0.5 mM DTT, and the pH was set to 7.1. The tissue was 
washed in respiration solution, consisting of 110 mM sucrose, 0.5 mM EGTA, 17 mM  MgCl2, 20 mM taurine, 
60 mM K-lactobionate, 10 mM  KH2PO4, 20 mM HEPES, 1 g/L BSA (fatty acid free), and pH set to 7.1 before 
being transferred to a respirometer (Oxygraph-2 k; Oroboros Instruments, Innsbruck, Austria). Oxygen concen-
tration remained < 300 μM during the experiment and temperature was set to 37 °C.
Leak respiration was measured during 10 mM sodium glutamate, 0.5 mM sodium malate and 5 mM sodium 
pyruvate. NADH-linked (through complex I) respiration was assessed using 2.5 mM ADP. Maximal NADH-
linked respiration was measured after 10 μM cytochrome c, i.e. after correcting for possible outer-membrane 
damage. Maximal oxidative phosphorylation capacity was determined after 10 mM succinate. Maximal uncou-
pled respiration was assessed after titrations of 0.01 μM carbonylcyanide-4-(trifluoromethoxy)-phenylhydrazone 
(FCCP). Succinate-driven (complex II) respiration was assessed by inhibiting mitochondrial complex I by 0.5 μM 
rotenone. Residual oxygen consumption was measured after 2.5 μM antimycin A and used for background cor-
rection. Experiments were performed in duplo. Respiration values were averaged and normalized to wet weight 
and expressed in pmol  O2/s/mg.
Mitochondrial complex protein determinations by Western immunoblotting. Protein content 
was determined using western immunoblotting. Tissue homogenates containing 7.5 or 12.5 µg (well within the 
linear range of detection) of protein were loaded onto a pre-cast 4–15% or 8–16% gradient criterion TGX SDS-
PAGE gels. Proteins were transferred onto PVDF membranes and incubated with an antibody cocktail (Abcam, 
Cambridge, UK; dilution 1:1,000; 2 h) against complex I subunit (NDUFB8), 30 kDa complex II subunit and 
complex IV subunit 1. Complex III subunit core 2 could not be determined due to species differences for the 
specificity of antibodies.
RnA extraction and gene expression analyses. From 20 mg snap-frozen sub-endocardial tissue sam-
ples of 3 Control and 3 DMetD pigs, total RNA was extracted using the Qiagen miRNeasy Mini kit protocol. 
RNA integrity was checked on an Agilent 2,100 Bioanalyser for a RIN score ≥ 8.0 and 20 μg RNA at 100 ng/μl 
was used for further analyses. At the Biomics center of Erasmus University Medical Center, RNA was prepared 
for sequencing with the Illumina TrueSeq RNA sample preparation kit. Sequencing was performed according to 
the Illumina TrueSeq v3 protocol on an Illumina HiSeq 2000 sequencing system, 43 bp single read, 7 bp index. 
Sequence data were mapped against the reference pig genome Sus scrofa sequence assembly version 10.2 by Illu-
mina Tophat version 2.0.10. Gene expression values of the RNA-seq data were estimated using  featureCounts17 
using the gene annotation Sscrofa10.2. Statistical differences in gene expression between both conditions were 
estimated using  edgeR18 where an absolute logFC > 1 with a P-value < 0.001 was considered statistically signifi-
cant. Biological functions and molecular networks of the differentially expressed genes were determined using 
Ingenuity pathway analysis Pathway analysis (Ingenuity Systems, Redwood City, CA, USA). Interconnectivity of 
the genes was visualized by the molecular networks constructed by the program.
Data analysis. Data are presented as mean ± SEM. Comparison of variables between the DMetD and Con-
trol animals over time was performed by two-way ANOVA for repeated measures (fitness, echocardiography, 
PV-loop, myocyte force and blood variables) and Bonferroni post-hoc test or unpaired student t-test (variables 
measured only once at sacrifice) by GraphPad Prism 4.3 or SAS 9.2. p < 0.05 was considered statistically signifi-
cant.
ethics approval and consent to participate. Studies were approved by the Animal Care Committee at 
Erasmus University Medical Center, Rotterdam, The Netherlands.
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consent for publication. All authors have read and approved submission of the final version of the manu-
script.
Results
Metabolic parameters and fitness. Several results are presented in the Supplementary Information file. 
Five months of DMetD resulted in hyperglycemia (p < 0.05), hypercholesterolemia (p < 0.05) and hypertriglyc-
eridemia (p < 0.05), while no significant differences in body weight were observed between the groups (Table 1). 
DMetD resulted in a significant reduction in physical fitness, as reflected in a ~ 30% decrease in total running 
time (p < 0.05 versus Control). 
Table 1.  Body weight (BW) and plasma metabolic parameters measured at baseline and 5-month time 
points. CON healthy controls (n = 8), DMetD diabetic metabolic derangement animals (n = 9), LDL low density 
lipoproteins *p < 0.05 as time·diabetes interaction by two-way ANOVA † p < 0.05 versus corresponding CON by 




CON 32 ± 2 37 ± 1
DMetD 31 ± 2 40 ± 3‡
Glucose (mmol/l)
CON 5.9 ± 0.4 6.8 ± 0.7
DMetD 5.0 ± 0.3 13.9 ± 2.0*†‡
Cholesterol (mmol/l)
CON 1.01 ± 0.13 1.10 ± 0.04
DMetD 0.98 ± 0.05 5.89 ± 1.03*†‡
LDL cholesterol (mmol/l)
CON 0.45 ± 0.09 0.39 ± 0.03
DMetD 0.42 ± 0.03 3.68 ± 1.05*†‡
Triglycerides (mmol/l)
CON 0.30 ± 0.02 0.27 ± 0.03
DMetD 0.26 ± 0.03 0.66 ± 0.19*†‡
Fitness test (min)
CON 39 ± 4 38 ± 4
DMetD 43 ± 5 30 ± 4*‡
Figure 1.  Ratio of mitral peak velocity during early filling (E) to early diastolic mitral annular velocity (e′, E/e′ 
ratio, A), peak left ventricle untwist velocity (B), left atrial volume (LA, C), left ventricle end diastolic diameter 
(LVEDD, D), posterior wall thickness (PWd, E), and relative wall thickness ((2*PWd)/LVEDD, F) in the hearts 
of DMetD and Control (CON) swine at baseline (BL) and after 5 months. *p < 0.05 for interaction DMetD and 
time by two-way ANOVA, †p < 0.05 versus corresponding CON by Bonferroni post-hoc test, and ‡p < 0.05 versus 
CON by unpaired t-test.
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cardiac function and remodeling. There were no differences in echocardiography variables between 
Control and DMetD at baseline (Tables S1 and S2). Five months of DMetD resulted in an elevated E/e’, while 
peak untwist velocity was significantly lower, in DMetD compared to Control (Fig. 1), indicating impaired LV 
diastolic function in DMetD. In contrast, DMetD did not produce differences in left atrial (LA) volume, LV 
diameter, or absolute and relative LV wall thickness between DMetD and Control (Fig. 1), while LV weight was 
also not affected (Fig. 2A), indicating that 5 months of DMetD did not result in cardiac remodeling. Moreover, 
there were no significant differences in LV and aortic pressures, LV volumes, stroke volume, ejection fraction, 
or cardiac output between DMetD and Control (Tables S3 and S4). Histological analysis showed that cardio-
myocyte size (Fig. 2B, C) and myocardial collagen content (Fig. 2E, F) were not significantly different between 
DMetD and Control. Furthermore, there were no changes in type I or type III collagen or their ratio (data not 
shown). These histological findings correlated well with the nearly identical LV weights and LV end-diastolic 
pressure–volume relations, (Fig. 2D), the preload recruitable stroke work (Fig. 2G), and preload adjusted dP/
dtmax (Fig. 2H) and dP/dtmin (Fig. 2I) in DMetD and Control. 
isolated cardiomyocyte function. Single cardiomyocyte passive force was significantly higher in 
the DMetD group compared to Control (Fig. 3A) as was the maximally developed force (Fig. 3B). No differences 
were observed in titin isoform composition evidenced by an unaltered ratio between the compliant (N2BA) and 
stiff (N2B) isoform of titin between DMetD and Control (Fig. 3C).
Reactive oxygen species and nitric oxide. Superoxide production in the LV myocardium was mark-
edly higher in DMetD compared to Control under baseline conditions as well as during inhibition of NOS and 
NADPH oxidase (Fig. 4A). Furthermore, upon stimulation of NADPH oxidase (Fig. 4B), superoxide production 
was further enhanced in the DMetD group, suggesting that NADPH oxidase is a significant source of superox-
ide. This increase was attenuated by L-NAME, both under basal conditions (Fig. 4A), as well as under NADPH 
stimulation (Fig. 4B), suggesting that a significant part of the superoxide production is NOS-dependent. eNOS 
expression in DMetD was comparable to Control (Fig. 4C), but the ratio between phosphorylated and unphos-
phorylated eNOS was reduced in DMetD (Fig. 4D). Moreover, monomer-to-dimer ratio was also significantly 
increased, suggestive of eNOS uncoupling (Fig. 4E), and NO production was reduced in DMetD (Fig. 4F). The 
decrease in eNOS phosphorylation and increase in eNOS uncoupling correlated with the superoxide production 
(both p < 0.05), further supporting the contribution of eNOS uncoupling to the oxidative stress in the hearts of 
DMetD animals.
Mitochondrial structure and function. Electron microscopy (EM) analysis of the cardiomyocytes 
(Fig. 5A, B) demonstrated increased glycogen content in the cardiomyocytes of DMetD compared to Control 
(Fig.  5C), indicating a clear diabetic phenotype. Additionally, more (and larger) vacuoles were observed in 
DMetD myocardium compared to Control (Fig. 5D), indicative of either fatty acid accumulation or enlarged sar-
coplasmic reticulum. Mitochondrial density (Fig. 5E) and percentage of interconnected mitochondria (Fig. 5F) 
were similar in both groups, suggesting that the network connectivity remained intact in DMetD. Total myo-
cardial mitochondrial complex protein content was slightly higher in DMetD (Fig. 5G and S3), but maximally 
uncoupled respiration (normalized to wet weight) was lower in DMetD compared to Control (− 20%, p < 0.05; 
Fig. 5H). This lower mitochondrial respiration could, at least in part, be explained by a lower maximal NADH 
(complex I)-stimulated respiration in DMetD compared to Control (− 31%, p = 0.02; Supplementary Fig. S4), 
while maximal complex II-linked respiration was similar (Fig S4), indicative of a mitochondrial complex I dys-
function in DMetD.
AMpK and metabolic enzymes. The analysis of AMPK light and heavy bands showed lower protein 
levels of the AMPK light bands in the DMetD animals (Fig. 6A), while no differences were observed in the heavy 
bands (Fig. 6B). The levels of pAMPK were also lower in the DMetD group (Fig. 6C). Enzyme activities of citrate 
synthase (CS), lactate dehydrogenase (LDH) and 3-OH acyl CoA dehydrogenase (HOAD) were similar between 
groups (Fig. 6D–F).
Genome-wide gene expression. Genome-wide gene expression analyses indicated that transcription of 
63 different genes were statistically significantly differentially expressed, with 29 genes up-regulated and 34 genes 
down-regulated by DMetD, of which many were related to alterations in glucose and fatty acid metabolism 
(Supplementary Table  S6). The most significantly affected networks were ‘glucose metabolism disorder’ and 
‘transport of lipids’ and within these networks we identified three transcriptional factors being involved, i.e. FOX 
A2, CEBPA and PPARA (Fig. 7).
Discussion
The present study was designed to investigate the early cardiac functional and structural abnormalities pro-
duced by DMetD in a human-like, translational large animal model, at the level of gene and protein expression, 
cellular and tissue composition as well as organ function. The main findings were that: (i) After five months 
of DMetD, no changes in LV weight, LV end-diastolic-pressure, -volume, and -pressure–volume relation, and 
LA volume were observed. Similarly, no LV myocardial fibrosis or cardiomyocyte hypertrophy was observed, 
indicating the absence of overt remodeling at the LV chamber or myocardial tissue level. (ii) In contrast, cardio-
myocyte resting tension was increased, which was accompanied by an elevated E/e’ and a lower LV peak untwist 
velocity in DMetD, reflecting early impairments in LV diastolic function. (iii) Mitochondrial dysfunction in 
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Figure 2.  Left ventricular weight (LV weight, (A)), myocyte cross-sectional area (examples, (B), and data 
summary (C)), end-diastolic pressure (EDP)–volume (EDV) relation composed from measurements at preload 
reduction, (inverted triangle), baseline (open circle) and preload increase (open triangle) (D), myocardial 
collagen deposition (examples, (E) and data summary (F)), stroke work (SW, G), and dP/dtmax (H) and dP/dtmin 
(I), plotted as a function of end-diastolic volume, measured at sacrifice in CON and DMetD animals.
Figure 3.  Single cardiomyocyte passive force (A) in response to increasing myocyte stretch and maximal 
forces (B). CON = controls (13 cardiomyocytes of 5 swine), DMetD, diabetic metabolic derangement (11 
cardiomyocytes of 5 swine). Myocardial titin N2BA/N2B ratio of CON (n = 6) and DMetD (n = 5, C), and typical 
examples of the titin gels for 3 animals in each group . *p < 0.05 versus CON by two-way ANOVA, †p < 0.05 
versus CON by unpaired t-test. Full-length gels are shown in Supplementary Fig. S1.
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DMetD swine was also present with lower mitochondrial complex I function and lower maximal respiration, 
despite minor changes in mitochondrial protein content or mitochondrial density. (iv) DMetD also resulted in 
marked perturbations in LV myocardial nitroso-redox balance, due to increased superoxide and reduced nitric 
oxide production. (v) These abnormalities were accompanied by differential expression of a significant number 
of genes, many of which related to perturbations in glucose and fatty acid metabolism. The implications of these 
findings will be discussed.
DMetD-associated LV diastolic dysfunction in the absence of LV remodeling. DMetD is a major 
risk factor for heart failure, in particular heart failure with preserved ejection fraction (HFpEF)19,20. HFpEF 
is characterized by an increased LV diastolic stiffness and LV concentric remodeling, while at the myocardial 
ultrastructural level fibrosis and concentric myocyte hypertrophy are typically  observed21,22. In the present 
study, 5  months of DMetD did result in robust hyperglycemia and dyslipidemia, with hypercholesterolemia 
and increased plasma triglycerides, in the absence of liver or kidney dysfunction (see Supplementary Table S5), 
consistent with our and others’ findings in similar animal  models7,23,24. However, despite these clear metabolic 
alterations DMetD did not—yet—result in LV or cardiomyocyte hypertrophy or increased LV end-diastolic stiff-
ness or produce myocardial fibrosis, suggesting that overt LV structural changes were still absent. Addition-
ally, no macroscopic atherosclerosis development could be observed at this point in any of the large epicardial 
coronary arteries. In contrast, we observed several functional changes both in LV chamber and cardiomyocyte 
function. Thus, peak untwist velocity—a novel and early functional marker of LV diastolic dysfunction—was 
lower, while E/e′—an established marker of diastolic dysfunction—was elevated in DMetD versus Control swine 
at 5 months of DMetD. Interestingly, we recently found that a reduction of peak untwist velocity was already 
observed after 3 months of DMetD, at a time when E/e′ was still maintained  normal25. The observation in the 
present study, that 5 months of DMetD produced a further reduction in peak untwist velocity and resulted in 
an elevated E/e′, suggests that diastolic dysfunction progresses over time. The described increase in E/e′ ratio 
and peak untwist velocity may be a reflection of the dysfunctional (subendocardial) cardiomyocytes as an early 
manifestation of diastolic dysfunction, before an overt increase in collagen deposition increases chamber stiff-
Figure 4.  Basal (A) and NAPDH-stimulated (B) superoxide production in LV myocardium, myocardial eNOS 
expression (C), phosphorylation of eNOS (D), the monomer/dimer ratio (E), and nitric oxide (NO) production 
(F). CON = controls (n = 8), DMetD, diabetic metabolic derangement (n = 9). *p < 0.05 versus corresponding 
CON by two-way ANOVA and Bonferroni post hoc (panel A and B) or unpaired t-test (panel C–F), †p < 0.05 
versus corresponding untreated by two-way ANOVA and Bonferroni post hoc, ‡p < 0.05 versus corresponding 
basal by two-way ANOVA and Bonferroni post hoc. Full-length gel blots are shown in Supplementary Fig. S2.
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ness more  profoundly26. This may explain why LVEDP and LV end-diastolic elastance, as assessed with LV pres-
sure–volume measurements, were still maintained at this stage of the disease. However, the lack of difference 
between DMetD and Control animals with respect to other early diastolic function variables, including Tau and 
LV dP/dtmin is not readily explained. One potential explanation is that echocardiography was performed under 
light sedation, while LV pressure–volume measurements were obtained under deep general anaesthesia with 
pentobarbital; the latter may have obscured subtle differences in early diastolic function parameters between 
DMetD and Control animals.
Indeed, the changes in LV diastolic function were accompanied by an increased passive force of single car-
diomyocytes, suggesting that altered cardiomyocyte function, rather than structural changes, were responsible 
for the observed LV diastolic dysfunction. A higher resting cardiomyocyte tension has been shown in patients 
with  HFpEF21,27 as well as in DMetD  patients28 and animal  models7,29,30. The increased resting tension has ini-
tially been ascribed to changes in titin isoform  expression31. However, in line with more recent studies suggest-
ing that changes in titin phosphorylation (rather than the isoform changes) are principally responsible for the 
increased resting  tension32,33, we also failed to observe differences in titin isoform expression. There is increasing 
evidence that hypo-phosphorylation of titin is the result of reduced NO-cGMP-PKG  signaling27,33. Interestingly, 
we observed a reduced nitric oxide production in DMetD swine, warranting further investigation of changes in 
titin phosphorylation in DMetD animals in future studies.
oxidative stress and impaired nitric oxide formation. Five months of DMetD resulted in substan-
tially higher superoxide production in LV myocardium compared to Control swine. Superoxide production 
Figure 5.  Examples of cardiomyocyte ultrastructure by electron microscopy in CON (A) and DMetD (B). 
M = mitochondrion, G = glycogen, V = vacuole. Scale bar represents 2 μm. The inserts highlight the altered 
glycogen content. Quantified glycogen content (C) and number of vacuoles (D) were significantly higher in 
DMetD compared to CON. Mitochondrial density (E) or percentage of connected mitochondria (F) were 
not different between groups. Total myocardial mitochondrial protein content (G) by Western blotting 
(see Supplementary Fig. 1) was significantly higher in DMetD compared to CON. Electron transport 
(ET) capacity (H) however, was significantly lower in DMetD compared to CON, due to NADH-linked 
dysfunction (see Supplementary Fig. 2), suggestive of an intrinsic mitochondrial dysfunction, independent 
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Figure 6.  Protein levels of the AMPK light (A) and heavy bands (B), pAMPK (C) and enzyme activity of CS 
(D), LDH (E) and HOAD (F), in CON and DMetD animals. *p < 0.05 versus CON by unpaired t-test. AMPK  
AMP-activated protein kinase, pAMPK phosphorylated AMPK, CS citrate synthase, LDH lactate dehydrogenase, 
HOAD 3-hydroxyacyl-CoA dehydrogenase. Full-length gel blots are shown in Supplementary Fig. S5.
Figure 7.  Myocardial genes and their networks in DMetD are connected to two major pathways associated with 
glucose and lipid metabolism disorders.
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was already significantly higher at basal state, which was principally NOS mediated. In addition, superoxide 
production was further aggravated in DMetD myocardium upon exposure to NADPH, which appeared to be 
mediated by both NOS and NADPH oxidase. These findings are in line with other studies demonstrating oxida-
tive stress in DMetD and suggest that a variety of mechanisms can contribute to oxidative stress in  DMetD34,35. 
Moreover, the increased superoxide production was likely directly related to abnormalities in NO bio-availabil-
ity. An increased NOS dependent superoxide production is consistent with our finding that monomer/dimer 
ratio of eNOS was significantly higher in DMetD myocardium. This suggests substantial eNOS uncoupling, 
which resulted in superoxide— rather than NO-production by eNOS. Moreover, although total eNOS was not 
different between the groups, the ratio of phosphorylated and unphosphorylated eNOS was reduced in DMetD, 
which may have been the result of the observed lower levels of AMPK and  pAMPK36,37. In line with these find-
ings, reduced NO levels, as indicated by the NO metabolites nitrite-and nitrate, were present in the DMetD 
myocardium. Reduced NO levels are not only detrimental for coronary vascular  function38, but also for myocar-
dial  function36,39, and the loss of NO, and consequently NO-cGMP-PKG signaling, likely explains the observed 
increase in cardiomyocyte resting  tension27.
AMpK and enzymatic activities in the LV. We observed an inhibition or deactivation of the AMPK 
system in DMetD, as we measured lower AMPK phosphorylation and AMPK light band levels. AMPK is an 
important regulator of cellular energy pathways and is activated by stressful situations such as prolonged exercise 
when AMP/ADP ratio is  elevated37,40. Unlike in rodents, in fish and swine two AMPK bands can be detected. 
The physiological meaning of these two bands has not been fully elucidated, but they may represent different iso-
forms of AMPK. The downregulation of AMPK was likely the result of the increased circulating glucose and lipid 
levels in conjunction with the higher tissue glycogen levels in DMetD swine, which was previously observed also 
in mouse models of  DMetD41,42. A decrease in AMPK activity explains, at least in part, the increased NADPH 
oxidase activity as well as the reduced peNOS levels in DMetD swine, and thus likely contributed to the pertur-
bations in nitroso-redox signaling and the consequent increase in cardiomyocyte resting  tension37.
Metabolic and mitochondrial function. Myocardial glycogen content was higher in DMetD, which is 
consistent with findings in previous  studies43,44. The higher number of vacuoles in the DMetD LV myocardium 
likely reflects increased fat deposits, but could also be part of enlarged peroxisomes (for fatty acid oxidation) 
or sarcoplasmic reticulum. Unfortunately, delineation between these possibilities cannot be derived from our 
electron microscopy images. However, the lack of functional alterations in systolic cardiac function in DMetD 
suggests that the sarcoplasmic reticulum remains intact in this animal model and these enlarged vacuoles are 
likely related to lipid overload, and a state of  lipotoxicity6.
Additionally, mitochondrial density and connectivity were not affected in DMetD, while total mitochondrial 
complex protein content was slightly higher. No significant alterations were detected in the maximal activity of 
myocardial enzymes essentially involved in cardiomyocyte energy generation, including CS, LDH and HOAD. 
Maximally stimulated mitochondrial respiration was lower in DMetD, due to a lower NADH-linked (complex I) 
respiration. Mitochondrial complex I is the most vulnerable complex for mitochondrial (supercomplex) damage, 
and dysfunction has been seen in other models of heart  failure16, and type 2 diabetes  mellitus45. Likely, the mito-
chondrial complex I dysfunction causes bioenergetic dysfunction and ADP insensitivity of the heart, contributing 
to ADP-induced stiffening of the  heart46. The cause of this impaired mitochondrial complex I function is currently 
unknown, but could relate to local inflammation and/or lipotoxicity,6,45 or oxidative stress-induced alterations in 
supercomplex  formation6, 16 that in turn can cause an increase in mitochondrial superoxide  formation47. Further 
studies are required to understand the contribution of mitochondrial dysfunction and the role of oxidative stress 
in the development of diastolic dysfunction in DMetD.
Gene expression profiles. Our genome-wide gene expression data analysis indicated that after 5 months 
of DMetD transcription of 364 different genes was either up-or down-regulated by DMetD by at least twofold. 
From these 364 genes two highly significant networks emerged that were related to abnormalities in glucose 
metabolism (glucose metabolism disorder) and fatty acid metabolism (transport of lipid). After p-value correc-
tion (FDR < 0.1), 63 genes remained statistically significant, of which several genes are particularly relevant in 
relation to the diabetic cardiomyopathy.
First, the upregulation of UCP3 (uncoupling protein 3) which results in dissipation of energy as heat, can 
protect mitochondria against lipotoxicity and lipid-induced oxidative stress, observed here. Expression levels 
of UCP3 increase when fatty acid supply to mitochondria exceeds their beta-oxidation capacity and the protein 
enables the export of excess fatty acid load from  mitochondria48. Another upregulated gene, ANGPTL4, encodes 
for the protein Angiopoietin-like 4, of which expression is induced by low oxygen levels and is also directly 
involved in regulating lipid metabolism. In diabetes, increased expression leads to reduced triglyceride clearance 
in blood, and explains, at least in part, the observed hypertriglyceridemia in DMetD swine. Additionally, we 
observed upregulated CPT1A, carnitine palmitoyltransferase 1A, which has a rate-limiting role for long chain 
fatty acid oxidation in cardiac mitochondria. Its expression has been shown to be increased in hypertrophied 
rat  cardiomyocytes49, resulting in impaired fatty acid  oxidation50. Although the mechanisms responsible for 
such increase in the present study are unclear, and may be related to an impaired inhibition of malonyl-CoA by 
glucagon in the DMetD hearts, it may contribute to accumulation of fatty acid metabolites in the myocardium, 
contributing to the increased  lipotoxicity50. Lipase E was also up-regulated in DMetD hearts, and is known to 
regulate hydrolysis of stored triglycerides to free fatty acids. Perilipin 2 (PLIN2) coats intracellular lipid storage 
droplets, and its up-regulation together with lipase E indicates enhanced free fatty acid traffic in the DMetD 
myocardium, and suggests that the higher number of vacuoles in DMetD indeed represent lipid accumulation. 
12
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:13173  | https://doi.org/10.1038/s41598-020-68637-4
www.nature.com/scientificreports/
The protein encoded by the CREB3L3 is a transcription factor that may act during endoplasmic reticulum stress 
by activating unfolded protein response target genes, suggesting that endoplasmic reticulum stress is present in 
the DMetD  myocardium51.
Out of the most down-regulated genes (largest fold-change), the physiological meaning of the protein encoded 
by GNMT gene (an enzyme that catalyzes the conversion of S-adenosyl-l-methionine to S-adenosyl-l-homo-
cysteine and sarcosine) is currently unclear in the diabetic heart. The observed down-regulation of SLC2A1 gene, 
which normally provides instructions for producing glucose transporter protein type 1 (GLUT1) is consistent 
with reduced glucose uptake in diabetic  myocardium52. Furthermore, HAPLN3 (Hyaluronan and proteoglycan 
link protein 3) has previously been associated with diabetes in epidemiological studies. The ALDH4A1 gene codes 
for the enzyme delta-1-pyrroline-5-carboxylate dehydrogenase, which is a mitochondrial matrix NAD-dependent 
dehydrogenase producing glutamate; its down-regulation confirms early impairments in NADH-linked res-
piration. Down-regulation of CYP4F55 (cytochrome P450) also suggests overall alterations in mitochondrial 
substrate oxidation, but the role of the cytochrome P450 system in the heart is largely  unknown53.
Although we did not investigate the causal relation between the observed alterations in gene-expression and 
the cardiac phenotype in DMetD animals, it could be speculated that some of these genes, expecially those related 
to mitochondrial function, could serve as potential drug targets to treat diabetic cardiomyopathy. Future stud-
ies are therefore needed to determine the therapeutic potential of interfering with (or enhancing) the DMetD-
induced alterations in gene-expression.
conclusions
The present study shows that diabetic metabolic derangement in a large animal model, with high resemblance 
to the human heart, resulted in myocardial oxidative stress, eNOS uncoupling and reduced NO production, 
together with an altered metabolic gene expression profile and mitochondrial dysfunction. These myocardial 
tissue alterations were associated with cardiomyocyte stiffening and early left ventricular diastolic dysfunction, 
before any overt structural cardiac remodeling occurs. Therapies should be directed to ameliorate these early 
DMetD-induced myocardial changes to prevent the development of overt cardiac failure.
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author upon reasonable request.
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